Geron Corporation

Geron Corporation is a late-stage clinical biopharmaceutical company that focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. Founded in 1990, the company is headquartered in Foster City, California, and is dedicated to pioneering innovative treatments for hematologic myeloid malignancies.

Geron Corporation’s primary therapeutic focus is on imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials. Imetelstat is designed to inhibit the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

Geron Corporation has a long-term commitment to developing innovative treatments for hematologic myeloid malignancies and is currently conducting clinical trials for imetelstat. The company has also established partnerships with leading biopharmaceutical companies, such as Johnson & Johnson, to develop and commercialize its products. In addition, Geron Corporation is actively engaged in research and development activities to identify new therapeutic targets and compounds that may be useful in treating hematologic malignancies.

Geron Corporation is also actively involved in the community, regularly supporting healthcare initiatives and patient advocacy groups. The company has also been recognized for its commitment to corporate social responsibility, receiving the Corporate Citizenship Award from the California Life Sciences Association in 2018.